HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyaka, P. N. Articles by McGhee, J. R. Search for Related Content PubMed PubMed Citation Articles by Boyaka, P. N. Articles by McGhee, J. R.

Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity¹

Prosper N. Boyaka^2,*,, Mariarosaria Marinaro^3,*, Raymond J. Jackson^*,, Frederik W. van Ginkel^*,, Estelle Cormet-Boyaka, Kevin L. Kirk, Charlotte R. Kensil^§ and Jerry R. McGhee^*,

Departments of ^* Microbiology and Physiology and Biophysics and Immunobiology Vaccine Center, University of Alabama, Medical Center, Birmingham, AL 35294; and ^§ Aquila Biopharmaceuticals, Inc., Framingham, MA 01702

The highly purified saponin derivative, QS-21, from the Quillaja saponaria Molina tree has been proved to be safe for parenteral administration and represents a potential alternative to bacterial enterotoxin derivatives as a mucosal adjuvant. Here we report that p.o. administration of QS-21 with the vaccine protein tetanus toxoid elicited strong serum IgM and IgG Ab responses, which were only slightly enhanced by further oral immunization. The IgG Ab subclass responses were predominantly IgG1 followed by IgG2b for the 50-µg p.o. dose of QS-21, whereas the 250-µg p.o. dose also induced IgG2a and IgG3 Abs. Low oral QS-21 doses induced transient IgE Ab responses 7 days after the primary immunization, whereas no IgE Ab responses were seen in mice given the higher QS-21 dose. Further, low but not high p.o. QS-21 doses triggered Ag-specific secretory IgA (S-IgA) Ab responses. Th cell responses showed higher IFN- (Th1-type) and lower IL-5, IL-6, and IL-10 (Th2-type) secretion after the high QS-21 p.o. dose than after low doses. Interestingly, the mucosal adjuvant activity of low oral QS-21 doses was diminished in IL-4^-/- mice, suggesting a role for this cytokine in the initiation of mucosal immunity by oral QS-21. In summary, our results show that oral QS-21 enhances immunity to coadministered Ag and that different doses of QS-21 lead to distinct patterns of cytokine and serum Ab responses. We also show that an early IL-4 response is required for the induction of mucosal immunity by oral QS-21 as adjuvant.

This article has been cited by other articles:

				M. Li, C. F. Cuff, and J. Pestka Modulation of Murine Host Response to Enteric Reovirus Infection by the Trichothecene Deoxynivalenol Toxicol. Sci., September 1, 2005; 87(1): 134 - 145. [Abstract] [Full Text] [PDF]

				A. R. Mathers and C. F. Cuff Role of Interleukin-4 (IL-4) and IL-10 in Serum Immunoglobulin G Antibody Responses following Mucosal or Systemic Reovirus Infection J. Virol., April 1, 2004; 78(7): 3352 - 3360. [Abstract] [Full Text] [PDF]

				P. N. Boyaka, A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen J. Immunol., June 1, 2003; 170(11): 5636 - 5643. [Abstract] [Full Text] [PDF]